Serum levels of soluble CD26/Dipeptidyl peptidase-IV in type 2 diabetes mellitus and its association with metabolic syndrome and therapy with antidiabetic agents in malaysian subjects

PLoS ONE

Volumn 10, Issue 10, 2015, Pages

  Ahmed, Radwan H ^a   Huri, Hasniza Zaman ^a   Al Hamodi, Zaid ^a   Salem, Sameer D ^b   Muniandy, Sekaran ^c  

^a UNIVERSITY OF MALAYA   (Malaysia)

^b UNIVERSITY MALAYA MEDICAL CENTRE   (Malaysia)

^c SANA A UNIVERSITY   (Yemen)

Author keywords

[No Author keywords available]

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; DIPEPTIDYL PEPTIDASE IV; GLUCAGON LIKE PEPTIDE 1; GLUCOSE; HEMOGLOBIN A1C; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INSULIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; METFORMIN; SULFONYLUREA DERIVATIVE; TRIACYLGLYCEROL; ANTIDIABETIC AGENT; GLYCOSYLATED HEMOGLOBIN; HEMOGLOBIN A1C PROTEIN, HUMAN;

ADULT; ARTICLE; BODY MASS; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; DISEASE ASSOCIATION; FEMALE; GLUCOSE BLOOD LEVEL; GLUCOSE HOMEOSTASIS; HEMOGLOBIN BLOOD LEVEL; HUMAN; INSULIN BLOOD LEVEL; MAJOR CLINICAL STUDY; MALAYSIAN; MALE; METABOLIC SYNDROME X; NON INSULIN DEPENDENT DIABETES MELLITUS; PROTEIN BLOOD LEVEL; TRIACYLGLYCEROL BLOOD LEVEL; BLOOD; CASE CONTROL STUDY; CHEMISTRY; COMPLICATION; DIABETES MELLITUS, TYPE 2; DIET RESTRICTION; MALAYSIA; METABOLISM; MIDDLE AGED; SOLUBILITY;

CASE-CONTROL STUDIES; DIABETES MELLITUS, TYPE 2; DIPEPTIDYL PEPTIDASE 4; FASTING; FEMALE; GLUCAGON-LIKE PEPTIDE 1; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPOGLYCEMIC AGENTS; MALAYSIA; MALE; METABOLIC SYNDROME X; METFORMIN; MIDDLE AGED; SOLUBILITY;

EID: 84949482350     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0140618     Document Type: Article

References (43)

1. Bell GI, Polonsky KS. Diabetes mellitus and genetically programmed defects in-cell function. Nature. 2001; 414(6865):788-91
2. International Diabetes Federation. Diabetes Atlas, 6th edn. International Diabetes Federation, 2013. 2014
3. Matteucci E, Giampietro O. Dipeptidyl Peptidase-4 (CD26): Knowing the Function before Inhibiting the Enzyme. Current Medicinal Chemistry. 2009; 16(23):2943-51
4. Cordero OJ, Salgado FJ, Nogueira M. On the origin of serum CD26 and its altered concentration in cancer patients. Cancer immunology, immunotherapy. 2009; 58(11):1723-47. doi: 10.1007/s00262-009-0728-1
5. Lamers D, Famulla S, Wronkowitz N, Hartwig S, Lehr S, Ouwens DM, et al. Dipeptidyl peptidase 4 is a novel adipokine potentially linking obesity to the metabolic syndrome. Diabetes. 2011; 60(7):1917-25. doi: 10.2337/db10-1707
6. Ussher JR, Drucker DJ. Cardiovascular biology of the incretin system. Endocrine reviews. 2012; 33 (2):187-215. doi: 10.1210/er.2011-1052
7. Morimoto C, Schlossman SF. The structure and function of CD26 in the Tcell immune response. Immunological reviews. 1998; 161(1):55-70
8. Durinx C, Lambeir A-M, Bosmans E, Falmagne J-B, Berghmans R, Haemers A, et al. Molecular characterization of dipeptidyl peptidase activity in serum: Soluble CD26/dipeptidyl peptidase IV is responsible for the release of X-Pro dipeptides. FEBS European Journal of Biochemistry. 2000; 267(17):5608-13
9. Matsuzawa Y. The role of fat topology in the risk of disease. International journal of obesity. 2008; 32: S83-S92. doi: 10.1038/ijo.2008.243
10. Heilbronn LK, Campbell LV. Adipose tissue macrophages, low grade inflammation and insulin resistance in human obesity. Current pharmaceutical design. 2008; 14(12):1225-30
11. Shirakawa J, Fujii H, Ohnuma K, Sato K, Ito Y, Kaji M, et al. Diet-Induced Adipose Tissue Inflammation and Liver Steatosis Are Prevented by DPP-4 Inhibition in Diabetic Mice. Diabetes. 2011; 60(4):1246-57. doi: 10.2337/db10-1338
12. Barnett A. DPP-4 inhibitors and their potential role in the management of type 2 diabetes. IJCP International Journal of Clinical Practice. 2006; 60(11):1454-70
13. Scheen AJ. DPP-4 inhibitors in the management of type 2 diabetes: a critical review of head-to-head trials. Diabetes &metabolism. 2012; 38(2):89-101
14. Blaslov K, Bulum T, Duvnjak L. Circulating dipeptidyl peptidase-4 activity is associated with insulin resistance in type 1 diabetic patients. Journal of diabetes and its complications. 2015; 29(3):390-4. doi: 10.1016/j.jdiacomp.2014.12.019
15. Yang F, Zheng T, Gao Y, Baskota A, Chen T, Ran X, et al. Increased plasma DPP4 activity is an independent predictor of the onset of metabolic syndrome in Chinese over 4 years: result from the China National Diabetes and Metabolic Disorders Study. PloS one. 2014; 9(3).
16. Kobayashi H, Hosono O, Mimori T, Kawasaki H, Dang NH, Tanaka H, et al. Reduction of serum soluble CD26/dipeptidyl peptidase IV enzyme activity and its correlation with disease activity in systemic lupus erythematosus. The Journal of rheumatology. 2002; 29(9):1858-66
17. Lee SA, Kim YR, Yang EJ, Kwon E-J, Kim SH, Kang SH, et al. CD26/DPP4 levels in peripheral blood and T cells in patients with type 2 diabetes mellitus. The Journal of Clinical Endocrinology &Metabolism. 2013; 98(6):2553-61
18. Busso N, Wagtmann N, Herling C, Chobaz-Péclat V, Bischof-Delaloye A, So A, et al. Circulating CD26 is negatively associated with inflammation in human and experimental arthritis. The American journal of pathology. 2005; 166(2):433-42
19. McKillop AM, Duffy NA, Lindsay JR, O'Harte FP, Bell PM, Flatt PR. Decreased dipeptidyl peptidase-IV activity and glucagon-like peptide-1 (7-36) amide degradation in type 2 diabetic subjects. Diabetes research and clinical practice. 2008; 79(1):79-85
20. Feron D, Begu-Le Corroller A, Piot J-M, Frelicot C, Vialettes B, Fruitier-Arnaudin I. Significant lower VVH7-like immunoreactivity serum level in diabetic patients: evidence for independence from metabolic control and three key enzymes in hemorphin metabolism, cathepsin D, ACE and DPP-IV. Peptides. 2009; 30(2):256-61. doi: 10.1016/j.peptides.2008.11.004
21. Firneisz G, Varga T, Lengyel G, Fehér J, Ghyczy D, Wichmann B, et al. Serum dipeptidyl peptidase-4 activity in insulin resistant patients with non-Alcoholic fatty liver disease: a novel liver disease biomarker. PLoS One. 2010; 5(8):e12226. doi: 10.1371/journal.pone.0012226
22. Ryskjaer J. Plasma dipeptidyl peptidase-IV activity in patients with type-2 diabetes mellitus correlates positively with HbAlc levels, but is not acutely affected by food intake. European Journal of Endocrinology. 2006; 155(3):485-93
23. Fadini GP, Albiero M, Menegazzo L, de Kreutzenberg SV, Avogaro A. The increased dipeptidyl peptidase-4 activity is not counteracted by optimized glucose control in type 2 diabetes, but is lower in metformin-treated patients. DOM Diabetes, Obesity and Metabolism. 2012; 14(6):518-22. doi: 10.1111/j. 1463-1326.2011.01550.x
24. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. Homeostasis model assessment: insulin resistance and b-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia: Clinical and Experimental Diabetes and Metabolism. 1985; 28(7):412-9
25. Alberti K, Eckel RH, Grundy SM, Zimmet PZ, Cleeman J, Donato K, et al. A joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity. Circulation. 2009; 120 (16):1640-5. doi: 10.1161/CIRCULATIONAHA.109.192644
26. Korosi J, McIntosh CH, Pederson RA, Demuth HU, Habener JF, Gingerich R, et al. Effect of aging and diabetes on the enteroinsular axis. The journals of gerontology Series A, Biological sciences and medical sciences. 2001; 56(9):575-9
27. Meneilly GS, Demuth HU, McIntosh CHS, Pederson RA. Effect of ageing and diabetes on glucosedependent insulinotropic polypeptide and dipeptidyl peptidase IV responses to oral glucose. DME Diabetic Medicine. 2000; 17(5):346-50
28. Mannucci E, Pala L, Ciani S, Bardini G, Pezzatini A, Sposato I, et al. Hyperglycaemia increases dipeptidyl peptidase IV activity in diabetes mellitus. Diabetologia. 2005; 48(6):1168-72
29. Pala L, Mannucci E, Pezzatini A, Ciani S, Sardi J, Raimondi L, et al. Dipeptidyl peptidase-IV expression and activity in human glomerular endothelial cells. Biochemical and Biophysical Research Communications. 2003; 310(1):28-31
30. Pala L, Ciani S, Dicembrini I, Bardini G, Cresci B, Pezzatini A, et al. Relationship between GLP1 levels and dipeptidyl peptidase4 activity in different glucose tolerance conditions. Diabetic Medicine. 2010; 27(6):691-5. doi: 10.1111/j.1464-5491.2010.03010.x
31. Ryskjr J, Deacon CF, Carr RD, Krarup T, Madsbad S, Holst J, et al. Plasma dipeptidyl peptidase-IV activity in patients with type-2 diabetes mellitus correlates positively with HbAlc levels, but is not acutely affected by food intake. European journal of endocrinology. 2006; 155(3):485-93
32. Aso Y, Terasawa T, Kato K, Jojima T, Suzuki K, Iijima T, et al. The serum level of soluble CD26/dipeptidyl peptidase 4 increases in response to acute hyperglycemia after an oral glucose load in healthy subjects: association with high-molecular weight adiponectin and hepatic enzymes. Translational Research. 2013; 162(5):309-16. doi: 10.1016/j.trsl.2013.07.011
33. Zhang F, Tang X, Cao H, Lü Q, Li N, Liu Y, et al. Impaired secretion of total glucagon-like peptide-1 in people with impaired fasting glucose combined impaired glucose tolerance. International journal of medical sciences. 2012; 9(7):574
34. Legakis IN, Tzioras C, Phenekos C. Decreased glucagon-like peptide 1 fasting levels in type 2 diabetes. Diabetes Care. 2003; 26(1):252
35. Blaslov K, Bulum T, Zibar K, Duvnjak L. Relationship between metabolic syndrome and mealinduced glucagon like peptide1 response in type 1 diabetic patients. Journal of diabetes. 2015; 7(3):340-6. doi: 10.1111/1753-0407.12194
36. Freeman JS. Role of the incretin pathway in the pathogenesis of type 2 diabetes mellitus. Cleveland Clinic journal of medicine. 2009; 76(Suppl 5):S12-S9. doi: 10.3949/ccjm.76.s5.03
37. Kusunoki M, Sato D, Nakamura T, Oshida Y, Tsutsui H, Natsume Y, et al. The Beneficial Effects of the DPP-4 Inhibitor Alogliptin on Hemoglobin A1c and Serum Lipids in Japanese Patients with Type 2 Diabetes. Drug research. 2015
38. Mannucci E, Pala L, Ciani S, Bardini G, Pezzatini A, Sposato I, et al. Hyperglycaemia increases dipeptidyl peptidase IV activity in diabetes mellitus. Diabetologia: Clinical and Experimental Diabetes and Metabolism. 2005; 48(6):1168-72
39. Zheng T, Chen T, Liu Y, Gao Y, Tian H. Increased plasma DPP4 activity predicts new-onset hypertension in Chinese over a 4-year period: possible associations with inflammation and oxidative stress. Journal of human hypertension. 2014
40. Lindsay JR, Duffy NA, McKillop AM, Ardill J, O'Harte FPM, Flatt PR, et al. Inhibition of dipeptidyl peptidase IV activity by oral metformin in Type 2 diabetes. DME Diabetic Medicine. 2005; 22(5):654-7
41. Green BD, Irwin N, Duffy NA, Gault VA, O'Harte FPM, Flatt PR. Inhibition of dipeptidyl peptidase-IV activity by metformin enhances the antidiabetic effects of glucagon-like peptide-1. European Journal of Pharmacology. 2006; 547(1-3):192-9
42. Lenhard JM, Croom DK, Minnick DT. Reduced serum dipeptidyl peptidase-IV after metformin and pioglitazone treatments. Biochemical and Biophysical Research Communications. 2004; 324(1):92-7
43. Liu Y, Hong T. Combination therapy of dipeptidyl peptidase-4 inhibitors and metformin in type 2 diabetes: rationale and evidence. DOM Diabetes, Obesity and Metabolism. 2014; 16(2):111-7. doi: 10.1111/dom.12128